Building on nature's blueprint to leverage the cell’s most powerful systems against disease
VantAI's evolutionary scoring learns from naturally occurring interfaces, allowing our generative models to design smaller, more glue-like molecules
Industry leading ternary complex modeling performance
Systematic prioritization between each target and the full spectrum of potential effectors, utilizing VantAI’s evolutionary Deep Learning
Identification and inaugural recruitment of novel effector platforms through advanced systems biology algorithms, powered by an industry-leading knowledge graph
Building on nature's blueprint to leverage the cell’s most powerful systems against disease
VantAI's evolutionary scoring learns from naturally occurring interfaces, allowing our generative models to design smaller, more glue-like molecules
Industry leading ternary complex modeling performance
Systematic prioritization between each target and the full spectrum of potential effectors, utilizing VantAI’s evolutionary Deep Learning
Identification and inaugural recruitment of novel effector platforms through advanced systems biology algorithms, powered by an industry-leading knowledge graph
ML-driven methodology leverages information about known protein-protein interactions to rapidly build new degraders that can effectively stabilize target-E3 interfaces.
Unique model predicts degradation based on millions of carefully curated protein stability data points.
The world's leading map of the ubiquitin proteasome system connects E3s to specific degron motifs.
Novel assay workflow for rapidly confirming degradation activity of hundreds of compounds against dozens of targets in vitro.
We power the design and development of novel therapies and find new uses for existing ones.
We partner with CROs and organ-on-a-chip companies to offer sponsors a full suite of integrated in silico and wet-lab solutions.
VantAI’s platform supports cutting-edge research at leading academic labs and non-profit institutions.
VantAI’s cutting-edge tools help the world’s sharpest biotech investors identify and assess opportunities.
ML-driven methodology leverages information about known protein-protein interactions to rapidly build new degraders that can effectively stabilize target-E3 interfaces.
We are obsessed with the potential of AI, but recognize the complexity of biology. It is our mission to see the two intersect in a way that brings maximum impact on disease.
By strategic design, VantAI does not pursue its own clinical pipeline, instead it is our vision to be the AI partner that furthers the potential of hundreds of pharmaceuticals and biotechs around the world.
Novel assay workflow for rapidly confirming degradation activity of hundreds of compounds against dozens of targets in vitro.
.png)
Our mission is to write the next chapter of induced proximity
We apply our technology to challenging disease targets, both internally and in close collaboration with the worlds leading pharmaceutical companies
We are a group of scientists and engineers, convinced that this is the decade AI changes drug discovery forever
MEET OUR TEAMIf you are looking for a role at the bleeding edge of artificial intelligence, where your impact is immediate and meaningful, this is it.
Apply your skills to help us tackle some of the most complex and meaningful scientific challenges on the planet.
Get in touch with us for any questions or comments regarding our abilities, career opportunities, or potential collaborations. We’d love to hear from you.
33 Irving Place
Floor 10
New York, NY
United States